Gina Mauro | Authors


Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLL

January 28, 2022

Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.